It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
To explore the performance of 99mTc-diethylene triaminepentaacetic acid (DTPA) SPECT/CT texture analysis in evaluating the activity of thyroid-associated ophthalmopathy (TAO) . This retrospective study examined 115 TAO patients from a single institution as an internal cohort and 58 TAO patients from another institution as an external validation set. Patients in the internal cohort were randomly divided into training (n = 81) and internal validation sets (n = 34). Radiomics signatures were constructed with the minimal redundancy maximal relevance and least absolute shrinkage and selection operator algorithms in training set. Multivariate logistic regression analysis was used to develop a clinical model and a combined clinical–radiomics model. Diagnostic performance of models was evaluated using receiver operating characteristic curve analysis, calibration curves and decision curve analysis. Compared with CT and SPECT radiomics models, Rad-scoreSPECT/CT demonstrated the best performance with areas under the receiver operating characteristic curve of 0.94 and 0.91 in the training and test sets, respectively. The combined clinical-radiomics model exhibited significantly better performance in evaluating TAO activity. Our results demonstrate the validity of a multimodal radiomic model of 99mTc-DTPA-SPECT/CT to assess TAO activity. The combined clinical-radiomics model exhibited significantly better diagnostic performance than the clinical model.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Huazhong University of Science and Technology, Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Wuhan, People’s Republic of China (GRID:grid.33199.31) (ISNI:0000 0004 0368 7223); Affiliated Renhe Hospital of China Three Gorges University, Department of Radiology, Yichang, People’s Republic of China (GRID:grid.254148.e) (ISNI:0000 0001 0033 6389)
2 Huazhong University of Science and Technology, Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Wuhan, People’s Republic of China (GRID:grid.33199.31) (ISNI:0000 0004 0368 7223); Hubei Province Key Laboratory of Molecular Imaging, Wuhan, People’s Republic of China (GRID:grid.412839.5) (ISNI:0000 0004 1771 3250); the Ministry of Education, Key Laboratory of Biological Targeted Therapy, Wuhan, People’s Republic of China (GRID:grid.419897.a) (ISNI:0000 0004 0369 313X)
3 Huazhong University of Science and Technology, Department of Ophthalmology, Union Hospital, Tongji Medical College, Wuhan, People’s Republic of China (GRID:grid.33199.31) (ISNI:0000 0004 0368 7223)
4 West China Hospital, Regenerative Medicine Research Center, Chengdu, People’s Republic of China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
5 Central South University, Department of Nuclear Medicine, The Third Xiangya Hospital, Changsha, People’s Republic of China (GRID:grid.216417.7) (ISNI:0000 0001 0379 7164)